ALT — Altimmune, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1326190 ·
Last close
$1.53
Market Cap
$297.72M
52W High
$6.44
52W Low
$1.50
ADV30
3,905,174
Next earnings
2026-11-12
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -35,705,000 -31,608,000 495,646,000 28,888,000 52,080,000
Jun 2026 0 — -26,229,000 -22,825,000 527,212,000 63,008,000 53,004,000
Mar 2026 0 — -24,244,000 -22,563,000 335,630,000 97,601,000 51,643,000
Dec 2025 26,000 — -28,893,000 -27,358,000 279,929,000 43,760,000 55,037,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-76,508,000
Investing CF
$-453,612,000
Financing CF
$410,023,000
CapEx
$-54,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.78
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-694,871,000
Inventory
—
Receivables
$3,341,000
ST Investments
$263,273,000
EBIT TTM
$-88,224,000
Pretax Income TTM
$-91,760,000
Interest Exp TTM
$3,536,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$26,000
EBITDA
$-113,496,000
Free Cash Flow
$-65,109,124
Enterprise Value
$91,242,648
Total Cash
$265,059,008
Total Debt
$36,202,000
Shares Out
194,589,451
Trailing EPS
$-0.71
Book Value
$2.28
ROE
-33.2%
ROA
-19.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 41,000 -94,489,000 -88,093,000 279,929,000 55,037,000 224,892,000 -67,535,000
Dec 2024 20,000 -103,172,000 -95,059,000 139,306,000 15,798,000 123,508,000 -79,848,000
Dec 2023 426,000 -83,510,000 -88,447,000 210,640,000 16,541,000 194,099,000 -75,810,000
Dec 2022 -68,000 -87,740,000 -84,713,000 206,928,000 21,635,000 185,293,000 -62,586,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$7,458,000
NetIncome TTM
$-91,760,000
OpCashFlow TTM
—
Assets (Latest)
$527,212,000
Forward EPS
$-0.70

Max Pain — expiry 2027-01-15

max pain strike: $2.00 · spot: $1.39 · call oi: 16,427 · put oi: 1,035
Expected Move to 2027-01-15: ±$0.80 (57.55%) — implied range $0.59 – $2.19 · ATM straddle on $1.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GALT GALECTIN THERAPEUTICS INC $293.47M $2.91 —
INO INOVIO PHARMACEUTICALS, INC. $305.31M $1.63 —
EVMN Evommune, Inc. $290.28M $7.02 —
EBS Emergent BioSolutions Inc. $288.44M $5.61 —
MPLT MapLight Therapeutics, Inc. $286.78M $6.57 —

News headlines (Yahoo Finance, 1h cache)

Altimmune, Inc. Q3 2026 Earnings Call Summary
2026-11-12 18:03 · Yahoo
Altimmune (ALT) Q3 2026 Earnings Call Transcript
2026-11-12 18:00 · Yahoo
What Altimmune (ALT) Said on Its Q3 Earnings Call
2026-11-12 16:15 · Yahoo
Altimmune Announces Third Quarter 2026 Financial Results and Business Update
2026-11-12 12:30 · Yahoo
Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology
2026-11-12 12:15 · Yahoo
Altimmune's Pemvidutide Meets Primary Endpoint in Phase 2 Alcohol Use Disorder Trial
2026-11-09 20:00 · Yahoo
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
2026-11-05 15:00 · Yahoo
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
2026-11-05 13:00 · Yahoo
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
2026-10-27 12:00 · Yahoo
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
2026-10-19 12:00 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-11-13 16:25:52 2026-11-13 Durso Jerome Benedict Pres, CEO P - Purchase 1.62 30700 49694